Mechanisms of mammalian target of rapamycin inhibition in sarcoma: present and future

被引：13
|
作者：
MacKenzie, Amy R. [1 ]
von Mehren, Margaret [1 ]
机构：
[1] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
来源：
EXPERT REVIEW OF ANTICANCER THERAPY | 2007年 / 7卷 / 08期
关键词：
AP23573; bone sarcoma; CCI-779; mammalian target of rapamycin; RAD001; sirolimus; soft-tissue sarcoma;
D O I：
10.1586/14737140.7.8.1145
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The mammalian target of rapamycin (mTOR) is a protein kinase that plays a pivotal role in the control of cell growth and development. A part of the PI3K/Akt pathway, mTOR responds to growth factor stimuli as well as nutrient availability by variations in downstream phosphorylation. Increasing knowledge of the upstream regulators and downstream targets of mTOR has led to the development of anticancer drugs that suppress protein synthesis and metabolism. Rapamycin (sirolimus) and three rapamycin analogues are currently being evaluated in clinical trials: temsirolimus (CCI-779, Wyeth), everolimus (RAD001, Novartis Pharma AG), and AP23573 (Ariad Pharmaceuticals Inc.). This review will highlight the role of these inhibitors in the treatment of sarcoma.
引用
收藏
页码：1145 / 1154
页数：10
相关论文
共 50 条
  • [41] Mammalian Target of Rapamycin as a target in hematological malignancies
    Abdel-Karim, Isam A.
    Giles, Francis J.
    CURRENT PROBLEMS IN CANCER, 2008, 32 (04) : 161 - 177
  • [42] Mammalian target of rapamycin as a target in hematological malignancies
    Kelly, Kevin R.
    Rowe, Julie H.
    Padmanabhan, Swaminathan
    Nawrocki, Steffan T.
    Carew, Jennifer S.
    TARGETED ONCOLOGY, 2011, 6 (01) : 53 - 61
  • [43] Mammalian target of rapamycin as a therapeutic target in osteoporosis
    Shen, Gengyang
    Ren, Hui
    Qiu, Ting
    Zhang, Zhida
    Zhao, Wenhua
    Yu, Xiang
    Huang, Jinjing
    Tang, Jingjing
    Liang, De
    Yao, Zhensong
    Yang, Zhidong
    Jiang, Xiaobing
    JOURNAL OF CELLULAR PHYSIOLOGY, 2018, 233 (05) : 3929 - 3944
  • [44] Mammalian target of rapamycin as a therapeutic target in leukemia
    Giles, FJ
    Albitar, M
    CURRENT MOLECULAR MEDICINE, 2005, 5 (07) : 653 - 661
  • [45] Inhibition of Mammalian Target of Rapamycin by Rapamycin Causes the Regression of Carcinogen-induced Skin Tumor Lesions
    Amornphimoltham, Panomwat
    Leelahavanichkul, Kantima
    Molinolo, Alfredo
    Patel, Vyomesh
    Gutkind, J. Silvio
    CLINICAL CANCER RESEARCH, 2008, 14 (24) : 8094 - 8101
  • [46] Mammalian Target of Rapamycin Inhibition With Rapamycin Mitigates Radiation-Induced Pulmonary Fibrosis in a Murine Model
    Chung, Eun Joo
    Sowers, Anastasia
    Thetford, Angela
    McKay-Corkum, Grace
    Chung, Su I.
    Mitchell, James B.
    Citrin, Deborah E.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (04): : 857 - 866
  • [47] Inhibition of mammalian target of rapamycin by rapamycin increases the radiosensitivity of esophageal carcinoma Eca109 cells
    Zhang, Dejun
    Xiang, Jie
    Gu, Yuming
    Xu, Wei
    Xu, Hao
    Zu, Maoheng
    Pei, Dongsheng
    Zheng, Junnian
    ONCOLOGY LETTERS, 2014, 8 (02) : 575 - 581
  • [48] Differential effects of rapamycin on mammalian target of rapamycin signaling functions in mammalian cells
    Edinger, AL
    Linardic, CM
    Chiang, GG
    Thompson, CB
    Abraham, RT
    CANCER RESEARCH, 2003, 63 (23) : 8451 - 8460
  • [49] Mammalian target of rapamycin inhibition in polycystic kidney disease: From bench to bedside
    Kim, Hyun-Jung
    Edelstein, Charles L.
    KIDNEY RESEARCH AND CLINICAL PRACTICE, 2012, 31 (03) : 132 - 138
  • [50] Targeted Inhibition of Mammalian Target of Rapamycin Signaling Inhibits Tumorigenesis of Colorectal Cancer
    Gulhati, Pat
    Cai, Qingsong
    Li, Jing
    Liu, Jianyu
    Rychahou, Piotr G.
    Qiu, Suimin
    Lee, Eun Y.
    Silva, Scott R.
    Bowen, Kanika A.
    Gao, Tianyan
    Evers, B. Mark
    CLINICAL CANCER RESEARCH, 2009, 15 (23) : 7207 - 7216
12345